Additional file 1 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Additional file 1: Table S1. List of clinical trials with non-engineered NK cell therapies. N = 36 clinical trials (Phase I, II, or I/II) evaluating the infusion of non-engineered allogeneic NK cell therapies in hematological or solid tumor patients were registered on ClinicalTrials.gov between March 2017 and December 2021. Studies are sorted by NK cell source (PB-NK, UCB-CD34, UCB-NK, iPSCs). The most relevant product characteristics and the clinical trial design and outcome (when available) are presented. Trial status is updated to August 2022. PB: peripheral blood; UCB: umbilical cord blood; iPSCs: induced pluripotent stem cells.